Wall Street analysts expect OptiNose Inc (NASDAQ:OPTN) to post $12.45 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for OptiNose’s earnings. The highest sales estimate is $12.50 million and the lowest is $12.40 million. OptiNose posted sales of $3.02 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 312.3%. The business is expected to report its next quarterly earnings results on Wednesday, March 4th.
According to Zacks, analysts expect that OptiNose will report full year sales of $35.98 million for the current financial year, with estimates ranging from $35.95 million to $36.00 million. For the next year, analysts anticipate that the company will post sales of $86.75 million, with estimates ranging from $83.10 million to $90.39 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that that provide coverage for OptiNose.
OptiNose (NASDAQ:OPTN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.69). OptiNose had a negative return on equity of 137.60% and a negative net margin of 419.37%. The company had revenue of $12.40 million for the quarter, compared to the consensus estimate of $8.56 million.
In related news, Director Joseph C. Scodari acquired 6,100 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The shares were bought at an average price of $8.64 per share, with a total value of $52,704.00. Also, major shareholder Avista Capital Partners Ii Gp, sold 1,250,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.17, for a total value of $11,462,500.00. The disclosure for this sale can be found here. 44.30% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in OptiNose by 6.5% in the second quarter. JPMorgan Chase & Co. now owns 2,667,724 shares of the company’s stock valued at $17,073,000 after buying an additional 163,755 shares during the last quarter. BlackRock Inc. raised its stake in OptiNose by 15.9% in the second quarter. BlackRock Inc. now owns 1,918,914 shares of the company’s stock valued at $13,586,000 after buying an additional 263,667 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in OptiNose by 18.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,033,499 shares of the company’s stock valued at $7,234,000 after buying an additional 160,664 shares during the last quarter. Tamarack Advisers LP purchased a new stake in OptiNose in the third quarter valued at about $4,725,000. Finally, Wasatch Advisors Inc. purchased a new stake in OptiNose in the second quarter valued at about $4,746,000. Institutional investors own 68.31% of the company’s stock.
OPTN stock traded down $0.11 during trading on Friday, reaching $9.34. 260,563 shares of the company traded hands, compared to its average volume of 421,316. OptiNose has a 12 month low of $4.44 and a 12 month high of $11.66. The business has a 50 day simple moving average of $9.18 and a 200 day simple moving average of $7.42. The company has a market capitalization of $392.95 million, a price-to-earnings ratio of -3.49 and a beta of 0.75. The company has a debt-to-equity ratio of 1.67, a quick ratio of 4.66 and a current ratio of 4.81.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
See Also: What is quantitative easing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.